Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors

AIP Advances

Volumn 2, Issue 1, 2012, Pages

  Van De Ven, Anne L ^a   Wu, Min ^b   Lowengrub, John ^b   McDougall, Steven R ^c   Chaplain, Mark A J ^d   Cristini, Vittorio ^e,f   Ferrari, Mauro ^a   Frieboes, Hermann B ^g,h  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HERIOT WATT UNIVERSITY   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^f University of New Mexico   (United States)

^g NONE   (United States)

^h UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED DRUG DELIVERY; DISEASES; NANOPARTICLES; POROUS SILICON; TUMORS;

DRUG DELIVERY SYSTEM; INTRAVITAL MICROSCOPY; MICROENVIRONMENTS; OPTIMAL TRANSPORT; QUANTITATIVE MEASURES; SILICON PARTICLES; SOLID TUMORS; VASCULARIZATION;

TARGETED DRUG DELIVERY;

EID: 84870640641     PISSN: None     EISSN: 21583226     Source Type: Journal    
DOI: 10.1063/1.3699060     Document Type: Article

References (52)

1. Franziska Michor, Jan Liphardt, Mauro Ferrari, and Jonathan Widom, "What does physics have to do with cancer?," Nature reviews 11(9), 657-670 (2011).
2. M. Ferrari, "Frontiers in cancer nanomedicine: directing mass transport through biological barriers," Trends Biotechnol 28(4), 181-188 (2010).
3. Rakesh K. Jain, "Transport of Molecules, Particles, and Cells in Solid Tumors," Annual Review of Biomedical Engineering 1(1), 241-263 (1999). (Pubitemid 129740012)
4. S. Nie, "Understanding and overcoming major barriers in cancer nanomedicine," Nanomedicine (Lond) 5(4), 523-528 (2010).
5. J. Sinek, H. Frieboes, X. Zheng, and V. Cristini, "Two-dimensional chemotherapy simulations demonstrate fundamental transport and tumor response limitations involving nanoparticles," Biomed Microdevices 6(4), 297-309 (2004). (Pubitemid 39545749)
6. J. P. Sinek, S. Sanga, X. Zheng, H. B. Frieboes, M. Ferrari, and V. Cristini, "Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation," J Math Biol 58(4-5), 485-510 (2009).
7. H. B. Frieboes, M. E. Edgerton, J. P. Fruehauf, F. R. Rose, L. K. Worrall, R. A. Gatenby, M. Ferrari, and V. Cristini, "Prediction of drug response in breast cancer using integrative experimental/computational modeling," Cancer Res 69(10), 4484-4492 (2009).
8. Helen M. Byrne, "Dissecting cancer through mathematics: from the cell to the animal model," Nature reviews 10(3), 221-230 (2010).
9. J. S. Lowengrub, H. B. Frieboes, F. Jin, Y. L. Chuang, X. Li, P. Macklin, S. M. Wise, and V. Cristini, "Nonlinear modelling of cancer: bridging the gap between cells and tumours," Nonlinearity 23(1), R1-R9 (2010).
10. I. M. van Leeuwen, C. M. Edwards, M. Ilyas, and H. M. Byrne, "Towards a multiscale model of colorectal cancer," World J Gastroenterol 13(9), 1399-1407 (2007). (Pubitemid 46630037)
11. Tiina Roose, S. Jonathan Chapman, and Philip K. Maini, "Mathematical Models of Avascular Tumor Growth," SIAM Rev. 49(2), 179-208 (2007). (Pubitemid 46888016)
12. Sergey Astanin and Luigi Preziosi, "Multiphase Models of Tumour Growth: Selected Topics in Cancer Modeling", (Birkhuser, Boston, 2008), pp. 1-31.
13. H. L. Harpold, E. C. Alvord, Jr., and K. R. Swanson, "The evolution of mathematical modeling of glioma proliferation and invasion," J Neuropathol Exp Neurol 66(1), 1-9 (2007). (Pubitemid 46066783)
14. A. R. Anderson and V. Quaranta, "Integrative mathematical oncology," Nature reviews 8(3), 227-234 (2008). (Pubitemid 351301842)
15. T. S. Deisboeck, L. Zhang, J. Yoon, and J. Costa, "In silico cancer modeling: is it ready for prime time?," Nat Clin Pract Oncol 6(1), 34-42 (2009).
16. A. C. Ventura, T. L. Jackson, and S. D. Merajver, "On the role of cell signaling models in cancer research," Cancer Res 69(2), 400-402 (2009).
17. A. R. Anderson and M. A. Chaplain, "Continuous and discrete mathematical models of tumor-induced angiogenesis," Bull Math Biol 60(5), 857-899 (1998). (Pubitemid 28427465)
18. S. R. McDougall, A. R. Anderson, M. A. Chaplain, and J. A. Sherratt, "Mathematical modelling of flow through vascular networks: implications for tumour-induced angiogenesis and chemotherapy strategies," Bull Math Biol 64(4), 673-702 (2002). (Pubitemid 36072687)
19. S. R. McDougall, A. R. Anderson, and M. A. Chaplain, "Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies," J Theor Biol 241(3), 564-589 (2006). (Pubitemid 44041121)
20. A. Stéphanou, S. McDougall, A. Anderson, and M. A. J. Chaplain, "Mathematical modelling of the influence of blood rheological properties upon adaptive tumour-induced angiogenesis," Math Comput Model 44, 96-123 (2006). (Pubitemid 44294552)
21. M. R. Owen, T. Alarcon, P. K. Maini, and H. M. Byrne, "Angiogenesis and vascular remodelling in normal and cancerous tissues," J Math Biol 58(4-5), 689-721 (2009).
22. P. Macklin, S. McDougall, A. R. Anderson, M. A. Chaplain, V. Cristini, and J. Lowengrub, "Multiscale modelling and nonlinear simulation of vascular tumour growth," J Math Biol 58(4-5), 765-798 (2009).
23. T. L. Jackson, "Intracellular accumulation and mechanism of action of doxorubicin in a spatio-temporal tumor model," J Theor Biol 220(2), 201-213 (2003). (Pubitemid 36027125)
24. E. S. Norris, J. R. King, and H. M. Byrne, "Modelling the response of spatially structured tumours to chemotherapy: drug kinetics," Math Comput Model 43, 820-837 (2006).
25. H. Enderling, M. A. Chaplain, A. R. Anderson, and J. S. Vaidya, "A mathematical model of breast cancer development, local treatment and recurrence," J Theor Biol 246(2), 245-259 (2007). (Pubitemid 46602362)
26. V. Cristini, J. Lowengrub, and Q. Nie, "Nonlinear simulation of tumor growth," J Math Biol 46(3), 191-224 (2003). (Pubitemid 38355715)
27. V. Cristini, H. B. Frieboes, R. Gatenby, S. Caserta, M. Ferrari, and J. Sinek, "Morphologic instability and cancer invasion," Clin Cancer Res 11(19 Pt 1), 6772-6779 (2005). (Pubitemid 41428730)
28. H. B. Frieboes, X. Zheng, C. H. Sun, B. Tromberg, R. Gatenby, and V. Cristini, "An integrated computational/experimental model of tumor invasion," Cancer Res 66(3), 1597-1604 (2006). (Pubitemid 43259943)
29. H. B. Frieboes, J. S. Lowengrub, S. Wise, X. Zheng, P. Macklin, E. L. Bearer, and V. Cristini, "Computer simulation of glioma growth and morphology," Neuroimage 37 Suppl 1, S59-70 (2007). (Pubitemid 47239426)
30. H. B. Frieboes, F. Jin, Y. L. Chuang, S. M. Wise, J. S. Lowengrub, and V. Cristini, "Three-dimensional multispecies nonlinear tumor growth-II: Tumor invasion and angiogenesis," J Theor Biol 264(4), 1254-1278 (2010).
31. S. Sanga, J. P. Sinek, H. B. Frieboes, M. Ferrari, J. P. Fruehauf, and V. Cristini, "Mathematical modeling of cancer progression and response to chemotherapy," Expert Rev Anticancer Ther 6(10), 1361-1376 (2006). (Pubitemid 44697162)
32. A. R. Anderson, A. M. Weaver, P. T. Cummings, and V. Quaranta, "Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment," Cell 127(5), 905-915 (2006). (Pubitemid 44792251)
33. P. Macklin and J. S. Lowengrub, "Nonlinear simulation of the effect of microenvironment on tumor growth," J Theor Biol 245, 677-704 (2007). (Pubitemid 46454401)
34. X. Zheng, S. M. Wise, and V. Cristini, "Nonlinear simulation of tumor necrosis, neo-vascularization and tissue invasion via an adaptive finite-element/level-set method," Bull Math Biol 67(2), 211-259 (2005). (Pubitemid 40234527)
35. M. Wu, H. B. Frieboes, S. McDougall, M. A. Chaplain, V. Cristini, and J. Lowengrub, "The effect of interstitial pressure on tumor growth and transport of therapeutic agents: coupling with the blood and lymphatic vascular systems," (Submitted).
36. A van de Ven, P. Kim, O. Haley, J. Fakhoury, G. Adriani, J. Schmulen, P. Moloney, F. Hussain, M. Ferrari, X. Liu, S. Yun, and P. Decuzzi, "Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution," JCR, In press. (2011).
37. P. Decuzzi, B. Godin, T. Tanaka, S.Y. Lee, C. Chiappini, X. Liu, and M. Ferrari, "Size and shape effects inthe biodistribution of intravascularly injected particles," J Control Release 141(3), 320-327 (2010).
38. Gu J., Godin B., Serda R. E., Ferrati S., Liu X., "Multistage mesoporous silicon-based nanocarriers: biocompatibility and controlled degradation in physiological fluids," 35th Annual Meeting & Exposition of the Controlled Release Society 575 (New York City, New York) (2008).
39. T. Tanaka, L. S. Mangala, P. E. Vivas-Mejia, R. Nieves-Alicea, A. P. Mann, E. Mora, H. D. Han, M. M. Shahzad, X. Liu, R. Bhavane, J. Gu, J. R. Fakhoury, C. Chiappini, C. Lu, K. Matsuo, B. Godin, R. L. Stone, A. M. Nick, G. Lopez-Berestein, A. K. Sood, and M. Ferrari, "Sustained small interfering RNA delivery by mesoporous silicon particles," Cancer Res 70(9), 3687-3696 (2010).
40. Huan Meng, Monty Liong, Tian Xia, Zongxi Li, Zhaoxia Ji, Jeffrey I. Zink, and Andre E. Nel, "Engineered Design of Mesoporous Silica Nanoparticles to Deliver Doxorubicin and P-Glycoprotein siRNA to Overcome Drug Resistance in a Cancer Cell Line," ACS Nano 4(8), 4539-4550 (2010).
41. Ji-Ho Park, Luo Gu, Geoffrey von Maltzahn, Erkki Ruoslahti, Sangeeta N. Bhatia, and Michael J. Sailor, "Biodegradable luminescent porous silicon nanoparticles for in vivo applications," Nat Mater 8(4), 331-336 (2009).
42. Biana Godin, Jianhua Gu, Rita E. Serda, Rohan Bhavane, Ennio Tasciotti, Ciro Chiappini, Xuewu Liu, Takemi Tanaka, Paolo Decuzzi, and Mauro Ferrari, "Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation," Journal of Biomedical Materials Research Part A 94A(4), 1236-1243 (2010).
43. Joseph J. Casciari, Stratis V. Sotirchos, and Robert M. Sutherland, "Variations in tumor cell growth rates and metabolism with oxygen concentration, glucose concentration, and extracellular pH," Journal of Cellular Physiology 151(2), 386-394 (1992).
44. D. D. Sumner and J. T. Stevens, "Pharmacokinetic factors influencing risk assessment: saturation of biochemical processes and cofactor depletion," Environ Health Perspect 102 Suppl 11, 13-22 (1994).
45. R. Ganapathi, H. Schmidt, D. Grabowski, M. Melia, and N. Ratliff, "Modulation in vitro and in vivo of cytotoxicity but not cellular levels of doxorubicin by the calmodulin inhibitor trifluoperazine is dependent on the level of resistance," British journal of cancer 58(3), 335-340 (1988).
46. C. Chiappini, E. Tasciotti, J. R. Fakhoury, D. Fine, L. Pullan, Y. C. Wang, L. Fu, X. Liu, and M. Ferrari, "Tailored porous silicon microparticles: fabrication and properties," Chemphyschem 11(5), 1029-1035 (2010).
47. P. Decuzzi, R. Pasqualini, W. Arap, and M. Ferrari, "Intravascular delivery of particulate systems: does geometry really matter?," Pharm Res 26(1), 235-243 (2009).
48. J. Lankelma, H. Dekker, F. R. Luque, S. Luykx, K. Hoekman, P. van der Valk, P. J. van Diest, and H. M. Pinedo, "Doxorubicin gradients in human breast cancer," Clin Cancer Res 5(7), 1703-1707 (1999). (Pubitemid 29334449)
49. A. J. Primeau, A. Rendon, D. Hedley, L. Lilge, and I. F. Tannock, "The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors," Clin Cancer Res 11(24 Pt 1), 8782-8788 (2005). (Pubitemid 43005929)
50. M. Ferrari, "Cancer nanotechnology: opportunities and challenges," Nature reviews 5(3), 161-171 (2005). (Pubitemid 40314948)
51. R. E. Serda, A. Mack, A. L. van de Ven, S. Ferrati, K. Dunner, Jr., B. Godin, C. Chiappini, M. Landry, L. Brousseau, X. Liu, A. J. Bean, and M. Ferrari, "Logic-embedded vectors for intracellular partitioning, endosomal escape, and exocytosis of nanoparticles," Small 6(23), 2691-2700 (2010).
52. M. Gutman, R.K. Singh, S. Yoon, K. Xie, C.D. Bucana, and I.J. Fidler, "Leukocyte-induced angiogenesis and subcutaneous growth of B16 melanoma," Cancer Biother 9(2), 163-170 (1994).